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Severe acute respiratory syndrome (SARS) is a disease characterized by diffuse alveolar damage. We isolated human alveolar type II cells and
maintained them in a highly differentiated state. Type II cell cultures supported SARS-CoV replication as evidenced by RT-PCR detection of viral
subgenomic RNA and an increase in virus titer. Virus titers were maximal by 24 h and peaked at approximately 105 pfu/mL. Two cell types within
the cultures were infected. One cell type was type II cells, which were positive for SP-A, SP-C, cytokeratin, a type II cell-specific monoclonal
antibody, and Ep-CAM. The other cell type was composed of spindle-shaped cells that were positive for vimentin and collagen III and likely
fibroblasts. Viral replication was not detected in type I-like cells or macrophages. Hence, differentiated adult human alveolar type II cells were
infectible but alveolar type I-like cells and alveolar macrophages did not support productive infection.
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SARS coronavirus (SARS-CoV) emerged in 2002–2003 and
presented primarily as a fulminant atypical pneumonia with a
case fatality rate of about 10%. Since its disappearance at the
end of the 2003 pandemic, the virus and the associated syn-
drome have been the focus of intense study. Pathologic studies
on the lungs of fatal cases often report the presence of marked
diffuse alveolar damage and uniformly report SARS-CoV
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doi:10.1016/j.virol.2007.09.045macrophages (CD68+ cells) (Ding et al., 2004; Franks et al.,
2003; Gu et al., 2005; He et al., 2006; Hwang et al., 2005;
Nicholls et al., 2006; Shieh et al., 2005; To et al., 2004; Ye et al.,
2007). These studies indicate that alveolar epithelial cells are
important cells involved with SARS infection and subsequent
diffuse alveolar damage and respiratory failure. When the al-
veolar epithelium is further differentiated into type I and type II
cells, the various studies report infection of one, the other, or
both cell types. The primary receptor of SARS-CoV was iden-
tified as angiotensin-converting enzyme 2 (ACE2) (Li et al.,
2003). ACE2 is distributed among numerous tissues, including
abundant expression on the pulmonary and intestinal epithelia
accounting for the pulmonary and GI symptoms observed with
infection (Hamming et al., 2004; He et al., 2006).
The alveolar epithelium consists of two main cell types. Type
I cells are thin, flat cells that cover over 90% of the alveolar
surface and comprise 8% of total lung cells (Stone et al., 1992a).
The primary function of the type I cells is to facilitate gas
Fig. 1. Type II cell cultures express ACE2 as well as the surfactant proteins.
Alveolar type II cells or Vero cells were cultured as described in the Methods
section, and extracts were prepared for immunoblotting. Type II cells were
cultured with specific additives on a Matrigel-rat tail collagen gel for 6 days and
type I-like cells were cultured on rat-tail collagen-coated wells. Lane 1 contains
the extract of freshly isolated type II cells; Lane 2 is a blank lane; Lane 3
contains extract of cells with 1% CS-FBS alone; Lane 4 1% CS-FBS+KAID;
Lane 5 5% FBS; Lane 6 5% FBS+KAID; Lane 7 5% FBS with cells on a
collagen-coated well (type I phenotype); Lane 8 blank lane; and Lane 9 Vero
cells. These results are representative of four separate experiments.
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Alveolar type II cells are cuboidal epithelial cells that comprise
15% of total lung cells and maintain the alveolar microenvi-
ronment through production and secretion of pulmonary sur-
factant, transepithelial sodium transport and alveolar fluid
homeostasis, proliferation to maintain the epithelium, and ulti-
mate transdifferentiation into type I cells (Mason, 2006). The
alveolar wall and air space also contains alveolar macrophages
and other inflammatory cells, endothelial cells, and fibroblasts
as well as cells within the microvasculature. All of the cells
could be theoretic targets for SARS-CoV infections, but ACE2
has been reported to be heavily expressed on alveolar type II
cells in the human lung (Ding et al., 2004; Hamming et al.,
2004; He et al., 2006).
Many in vitro models have been explored for their utility in
studying SARS-CoV infection of the pulmonary epithelium.
A549 cells, a lung carcinoma cell line that has been used as a
model of alveolar epithelial cells although it does not express
the surfactant proteins, has been refractory to SARS-CoV in-
fection unless provided with exogenous ACE2 despite expres-
sing some endogenous ACE2 (Gillim-Ross et al., 2004;
Hamming et al., 2004; Lieber et al., 1976; Mossel et al.,
2005). Calu-3 cells, a bronchial epithelial adenocarcinoma cell
line, are permissive to SARS-infection and are a useful model
for infection (Ren et al., 2006; Tseng et al., 2005). Two groups
have reported that differentiated airway ciliated cells can be
infected with SARS-CoV and that the infection correlated with
ACE2 expression (Jia et al., 2005; Sims et al., 2005). However,
infection of primary cultures of alveolar epithelial cells has not
been reported.
Using a multi-step isolation and purification technique, we
produced cultures of highly differentiated type II and type I-like
alveolar epithelial cells (Wang et al., 2007). Here we examine
the ability of SARS-CoV to infect these cell types. An under-
standing of the cells of the alveoli permissive to SARS-CoV
infection is an important step in understanding SARS patho-
genesis. We found that differentiated alveolar type II cells could
be infected with SARS-CoV. An unexpected finding in these
studies was the detection of SARS-CoV antigen in pulmonary
fibroblasts in our cultures. This is the first report of SARS-CoV
infection in differentiated adult human alveolar type II cells
in vitro.
Results
Characterization of primary human type II and type I-like
pneumocytes
The type II cell and type I-like cell cultures have been fully
characterized previously (Wang et al., 2007). The type II cell
cultures expressed the surfactant proteins SP-A, SP-B, and
proSP-C at the mRNA and protein level and had characteristic
lamellar inclusions and apical microvilli (Wang et al., 2007). As
shown in Fig. 1, these cells express SP-A and proSP-C as well
as fatty acid synthase (FAS) and ACE2 when cultured with
keratinocyte growth factor (KGF), isobutylmethylxanthine
(IBMX), 8-Br-cAMP (A), and dexamethasone (Dex, D) col-lectively referred to as KAID, in the presence of 1% charcoal-
stripped fetal bovine serum (CS-FBS). By both Western and
RNA analyses, ACE2 expression was highest in the presence
of KAID in 1% CS-FBS (Fig. 1 and data not shown). The type I-
like cells expressed caveolin-1, receptor for advanced glycated
end products (RAGE), and cytokeratin, but expression of
ACE2, SP-A, SP-B, and proSP-C was below the limit of de-
tection (Fig. 1 and data not shown) (Wang et al., 2007).
SARS-CoV replicates in type II but not type I-like alveolar cells
in vitro
Type I-like and type II cell cultures were infected with SARS
CoV at MOI=2–3, and supernatant titers were determined by
plaque assay at the indicated time points to determine their
ability to support SARS-CoV replication (Figs. 2A, B). Type II
cells cultured on the Millicell inserts proved difficult to wash
clean of residual inoculum resulting in relatively high titers
detected at 1 hpi. However, in each of the 11 different experi-
ments on cells isolated from nine different lungs, detectable
virus in the supernatant increased 10–100× at 24–48 hpi.
Maximal titers were generally reached by 24 hpi and were
maintained or dropped slightly through 72 hpi. Cytopathic
effect (CPE) was not detectable in the type II cell cultures. Type
I-like cells did not appear to support SARS-CoV replication.
After b0.5 log increase in detectable extracellular virus 24 hpi,
virus was undetectable in most cultures through 48 and 72 hpi
(n=6 different lungs for type I-like cell cultures). In addition,
alveolar macrophages did not support productive infection (data
not shown). For the type II cell donors, the age range was 21–
74 years (44±20 years, mean±S.D.) with nearly equal numbers
of men and women and smokers and nonsmokers. There was no
obvious effect of sex or smoking status on the results in this
small cohort. The type I-like cell cultures that did not support
Fig. 2. Virus replication in primary human alveolar type II cell and type I-like cell cultures. Cell monolayers were infected at MOI=2–3 after 7–8 days in culture. At
each time point, an aliquot of supernatant was removed and frozen for plaque assay. The results for type II cells are shown in Panel A and type I-like cells in Panel B.
Each curve represents virus growth in cells derived from different donor lungs and measured in three wells. The solid horizontal line indicates the assay limit of
detection.
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supported viral production.
These observations were confirmed by application of the
multiplex RT-PCRmethod previously described by Gillim-Ross
et al. (2004). This method allows for simultaneous amplification
of genomic and sub-genomic SARS-CoV RNA as well as a
GAPDH internal control. Vero E6, type II, and type I-like cell
cultures were infected at MOI=2–3. At the indicated time
points, RNAwas extracted from the monolayers and amplified.
1 hpi, SARS-CoV genomic RNA was present in all three in-
fected cultures (Fig. 3), indicative of incomplete removal of the
inoculum. SARS-CoV genomic and subgenomic RNA is pre-
sent 24 hpi in Vero E6 cells and 72 hpi in type II cell cultures,
further evidence of SARS-CoV replication in these cells. How-
ever, at 72 hpi, SARS-CoV genomic and subgenomic RNAwas
below the limit of detection in type I-like cells.Fig. 3. SARS-CoV genomic and subgenomic RNA in infected Vero E6, type II, and t
was extracted from the monolayers 24 hpi (Vero E6) or 72 hpi (type II and type I-lik
were simultaneously amplified by multiplex RT-PCR as described.Immunofluorescent staining of SARS-CoVinfected type II and
type I-like cell cultures
The 1–2 log increase in virus titer in the supernatants of type II
cell cultures, while reproducible, was unexpectedly low. Mono-
layers infected as above were immunostained with anti-SARS-N
to determine the extent of SARS-CoV infection and a variety of
cell markers to identify the cells infected. Within the type II cell
cultures, very few cells (estimated at b1 per 250) stained positive
for SARS-N (Figs. 4B, E, H, K, N, Q). Further, the SARS-N
positive cells had two distinct morphologies. One was small,
cuboidal cells typically appearing in large, cobbled islands, which
were type II cells, and the other was a larger flat or spindle-shaped
cell. The small, cuboidal cells stained positive for SP-A, cyto-
keratin, EP-CAM, and a type II cell-specific antibody obtained
from Dr. Leland Dobbs, University of California, San Franciscoype I-like cell cultures. Cell monolayers were infected at MOI=2–3. Total RNA
e cells). SARS-CoV genomic and subgenomic RNA and cellular GAPDH RNA
Fig. 4. SARS-CoV infection in primary human alveolar type II cell cultures. Type II cell cultures were stained with antibodies to SARS-CoV nucleocapsid (SARS-N)
protein (green), and a cellular marker (red). Each marker is shown in three frames: marker/DAPI, SARS-N/DAPI, and marker/SARS-N/DAPI. The small cuboidal cells
were positive for SP-A (A–C), cytokeratin (D–F), EP-CAM (G–I), and a type II cell monoclonal antibody (J–L). Cells positive for SARS-N were also positive for the
SARS-CoV receptor ACE2 (M–O). The larger spindle-shaped cells were vimentin positive (P–R).
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Fig. 5. Multinucleated cells expressing SARS-N protein. Type II cell cultures
were examined for the expression of SARS-CoV nucleocapsid protein (green).
Nuclei were stained with DAPI. (A) A tri-nucleated cell of cuboidal
morphology, likely of type II cell origin. (B) A bi-nucleated spindle shaped
cell. Cells on this filter were additionally stained for SP-A. The morphology of
this cell and the lack of SP-A staining suggest that this cell was derived from
fibroblasts in the culture.
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confirming their type II phenotype. These cells were also negative
for CD-31, CD-45, CD-68, collagen III and vimentin (data not
shown). The larger, spindle-shaped cells that stained positive for
SARS-N were vimentin (Figs. 4P–R) and collagen III positive
and were SP-A, cytokeratin, EP-CAM, CD-45, CD-68 and CD-
31 negative (data not shown), indicating that these infected cells
are fibroblasts. Within the type II cell cultures, a rare CD-31
positive cell could be identified as also being SARS-N positive,
indicating that endothelial cells may also be occasionally infected
with SARS-CoV.
As expected, the type II cells that were infected with SARS-
CoV were also positive for the SARS-CoV receptor, ACE2
(Figs. 4M–O). However, also evident were cells that were
positive for ACE2 but negative for SARS-CoV. None of the cells
in these cultures stained with the Oct-4 antibody (SC-9081,
Santa Cruz Biotechnology, Santa Cruz, CA, USA), which iden-
tifies a putative lung stem cell that can be infected with SARS
(Ling et al., 2006) (data not shown). Despite the low level of
infection in these cultures, we observed multinucleated cells of
both type II and the spindle-shaped morphology (Fig. 5).
Immunofluorescent staining of type I-like cell cultures indicated
less vimentin-positive cell contamination. Further, type I-like
monolayers were completely devoid of SARS-N staining (data
not shown).Fig. 6. SARS-CoV infection of fibroblasts. Five different lung fibroblast isolates w
experiment. Panel A is vimentin staining; panel B is SARS-N protein; and panel CSARS-CoV infects rare primary human lung fibroblasts
cultured in KAID-containing medium
Because we cannot further purify type II cells from the
contaminating cell types, we examined the replication of SARS-
CoV in primary human lung fibroblasts. Fibroblasts from five
donors were cultured on Millicell inserts under the same
conditions as the type II cell cultures. Fibroblasts from only one
of these donors appeared to support a limited replication of
SARS-CoV and these results were confirmed by immunohis-
tochemistry (Fig. 6). However, a later passage of this fibroblast
isolate that was initially positive for SARS was negative. Hence,
we were not able to confirm this initial finding.
Discussion
Models currently used in pathologic studies of SARS and
SARS-CoV in human cells are limited by two factors. First, most
cell culture models are not adequately representative of primary
cells or of cells in the context of tissue. Notable exceptions to this
are the bronchial epithelial cell models of Sims et al. (2005) and
Jia et al. (2005). Second, pathological specimens have the
advantage of examining primary cells in their natural context,
but by necessity have focused on the more severe or fatal cases,
in which there is excessive tissue injury and cell recognition is
difficult. It is not known if the diffuse alveolar damage is due
primarily to alveolar epithelial infection, a cytokine storm, or a
combination of these and other host factors, and if any special
cell–cell interactions or protease exposure is required for alve-
olar epithelial infections. In addition, as reviewed by Subbarao
and Roberts, animal models of SARS have significant limita-
tions and do not fully replicate the severe disease in humans
(Subbarao and Roberts, 2006).
In this report, we describe a model for the study of SARS-
CoV infection of primary human alveolar epithelial cells. In our
culture system, type II alveolar epithelial cells from all nine
donors supported SARS-CoV replication. Immunofluorescent
analysis suggests that viral replication occurs in a limited
number of cells within our cultures. Replication of SARS-CoV
did not, however, occur in the type I-like cells from any of the
six donors examined. However, it should be noted that while
these type I-like cells express many of the markers of type I cells
in vivo, they were derived from type II cells in vitro and may notere evaluated and only one was positive. This picture represents the positive
is the composite.
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also observed the occasional infection of pulmonary fibroblasts,
which was variable in different cultures. The number of con-
taminating fibroblasts varied with the donor and cell isolate.
Because infected type II cells and fibroblasts were observed
within the same cultures, it is not clear whether one or both of
the infections is productive. Cultured monocyte derived macro-
phages are not susceptible to SARS-CoV infection as deter-
mined by virus production (Cheung et al., 2005). We extended
this observation to human alveolar macrophages in primary
culture. These results contrast with the several pathological
studies that describe widespread detection of SARS-CoV RNA
and/or antigen in the alveolar epithelium, both in type II and type
I cells, though not always both cell types in every study (Ding
et al., 2004; Franks et al., 2003; Gu et al., 2005; He et al., 2006;
Hwang et al., 2005; Lang et al., 2003; Nicholls et al., 2006;
Shieh et al., 2005; To et al., 2004; Ye et al., 2007). In addition, in
these pathologic studies, alveolar macrophages were shown to
be positive for SARS-CoV antigen and/or RNA. Giant multi-
nucleated cells or syncytia within the lungs are characteristic of
fatal SARS-CoV infection, though these do not always represent
infected cells (Ding et al., 2003; Gu et al., 2005; Hwang et al.,
2005; Nicholls et al., 2006; To et al., 2004). The SARS-CoV
positive multinucleated giant cells can be derived from epithelial
cells (cytokeratin positive) or macrophages (CD-68 positive)
(Franks et al., 2003; Nicholls et al., 2003).
ACE2 has been previously reported to be expressed on type
II cells (Hamming et al., 2004; Wiener et al., 2007). In murine
lung, Weiner et al. recently reported ACE2 in type II cells, Clara
cells, and smooth muscle cells from small and medium vessels,
but not in type I cells or in capillaries in the alveolar wall
(Wiener et al., 2007). However, with our antibodies and immu-
nofluorescent techniques the level of expression of ACE2 is
below the limit of detection in most cells in our cultures. ACE2
expression in type II cell cultures was increased by the addition
of IL-13 to the basal medium but not to KAID medium in 1%
CS-FBS, and the addition of IL-13 did not result in increased
infection efficiency (data not shown). Additionally, as Figs.
4M–O demonstrates, numerous cells can be identified that
express ACE2 but do not appear to be infected with SARS-CoV.
It is possible that other factors contributed to the inefficiency
of SARS-CoV infection. Surfactant protein D (SP-D) might
aggregate the virus and inhibit infection. SP-A and SP-D are
secreted by type II cells and have a variety of immunoregulatory
functions. Recently SP-D has been reported to bind to the spike
glycoprotein on SARS-CoV (Leth-Larsen et al., 2007), and this
could possibly limit infection. Type II cells also produce nu-
merous cytokines that may have an effect on permissiveness to
SARS-CoV infection. Beta-defensin-2 is a protein produced by
type II cells shown in some cases to have direct anti-viral
activity (Ganz, 2002; Sun et al., 2005). Efforts were made to
remove surfactant proteins and other soluble factors from the
cultures at the time of infection, but none resulted in increased
infection efficiency. There also may be co-stimulating mole-
cules for receptor binding or cathepsins needed for maximal
viral infection that are missing from these primary cultures
(Huang et al., 2006). Therefore, ACE2 expression alone maynot account for the scarcity of infected cells. Another difference
between the in vitro situation and the in vivo situation is the low
volume of apical fluid such that a very high MOI likely exits in
vivo. The alveolar fluid volume in an adult human is thought to
be only 35 mL spread over a surface area of about 100 m2
(Stone et al., 1992b).
Another possible explanation for the low level of infection is
the choice of subjects. Pathological reports focus on clinical,
most often severe or fatal, cases of SARS. The cells used in this
study are acquired from random members of the populace. If
individuals progressing to severe disease represent a small
proportion of those exposed, then it is possible that by utilizing
cells from the general population, we are biasing our studies
toward mimicking mild or subclinical-type infections. Despite
these possibilities, the most likely explanation for the low level
of infection is that we have not discovered the means of
stimulating a high level of ACE2 expression throughout our
cultures.
The infection of fibroblasts was unexpected. Recently, more
detailed evaluation of pathologic material has indicated that
fibroblasts can be infected in vivo (Ye et al., 2007). In addition,
Lang et al. reported SARS RNA in interstitial cells as well as
type II cells and bronchiolar epithelial cells (Lang et al., 2003).
However, previous data indicated that fibroblast cell lines
(MRC-5, HEL) were not permissive to SARS-CoV infection
(Gillim-Ross et al., 2004; Kaye, 2006; Mossel et al., 2005). The
infection of fibroblasts may have been related to particular
characteristics of our cultures. The infection only occurred in
one of five low passage cultures of primary lung fibroblasts.
The infection that occurred in the one permissive sample was
much more apparent in 1% CS-FBS plus KAID than in media
with 5% FBS. The cells in our primary cultures of alveolar
epithelial cells were considered fibroblasts because they ex-
pressed vimentin and collagen III but not CD31 or CD45. It is
possible that these particular fibroblasts were derived from
epithelial cells by epithelial mesenchymal transition (EMT), but
we believe this possibility is unlikely. EMT in vitro requires
exogenous transforming growth factor beta (TGF-β), which
was not added to these cultures (Willis et al., 2005; Yao et al.,
2004).
In conclusion, we have developed an in vitro culture system
to evaluate SARS-CoV in highly differentiated adult human
type II cells. Type II cells could be infected with SARS-CoV but
we were unable to demonstrate productive infections with
alveolar macrophages or alveolar type I-like cells in vitro.
Methods
Cells and virus
Vero E6 cells (American Type culture Collection (ATCC),
Manassas, VA, USA) were propagated in MEM (Invitrogen,
Carlsbad, CA, USA) supplemented with 5% FBS. SARS-CoV
strain Urbani, obtained as a seed stock from Centers for Disease
Control and Prevention, Atlanta, GA, USA was propagated in
Vero E6 cells. All techniques using replication competent
SARS-CoV were performed under BSL-3 containment. SARS-
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previously (Sainz et al., 2004) with the modification that
SeaKem LE agarose (Cambrex, East Rutherford, NJ, USA) was
used in the overlays.
Isolation and culture of human alveolar type II and type I-like
cells
Type II cells were isolated from deidentified human lungs
that were not suitable for transplantation and donated for
medical research. The lungs were obtained through The Na-
tional Disease Research Interchange (Philadelphia, PA, USA)
and the International Institute for the Advancement of Medicine
(Edison, NJ, USA). The Committee for the Protection of Human
Subjects at National Jewish Medical and Research Center
approved this research. The isolation method has been pub-
lished previously (Wang et al., 2007). Briefly, the middle lobe
was perfused, lavaged, and then instilled with elastase
(12.9 units/mL, Roche Diagnostics, Indianapolis, IN, USA)
and incubated for 50 min at 37 °C. The lung was minced, and
the cells were isolated by filtration and partially purified by
centrifugation on a discontinuous density gradient made of
Optiprep (Accurate Chemical Scientific Corp., Westbury, NY,
USA) with densities of 1.080 and 1.040 and by negative
selection with CD-14-coated magnetic beads (Dynal Biotech
ASA, Oslo, Norway) and binding to IgG-coated Petri dishes
(Sigma Chemicals, Inc., St. Louis, MO, USA).
The isolated cells were resuspended in Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 10% FBS, 2 mM
glutamine, 2.5 μg/mL amphotericin B, 100 μg/mL streptomycin,
100 units/mL penicillin G, and 10 μg/mL gentamicin (Gibco
BRL, Rockville, MD, USA). The cells were plated on 4.2 cm2
Millicell inserts (Millipore Corp., Bedford, MA, USA) at a
density of 8×105/cm2 in DMEMwith 10% FBS. After 24–48 h,
the medium was changed to 1% CS-FBS, 10 ng/mL (KGF, K)
(R&D Systems, Inc., Minneapolis MN, USA), 0.1 mM (IBMX,
I), 0.1 mM 8-Br-cAMP (A), and 10 nM dexamethasone (Dex, D)
(Sigma) in addition to glutamine, amphotericin B, streptomycin,
penicillin, and gentamicin as above. Mediumwas replaced every
48 h. Some experiments utilized cells that were frozen down
after isolation, stored in liquid nitrogen, thawed and processed
the same as the fresh cells except that the plating density was
1×106 cells/cm2.
To transdifferentiate type II cells into type I-like cells, type II
cells were plated on rat tail collagen-coated dishes or collagen-
coated glass coverslips at a density of 0.5–1×105/cm2 in DMEM
with 10% FBS (Wang et al., 2007). After 24–48 h for adherence,
medium was changed to DMEM with 5% FBS without KAID
additives above and cultured for an additional 6 days (Wang et al.,
2007).
Isolation and culture of primary human lung fibroblasts
Fibroblasts were isolated from normal lung by a technique
reported previously (Frankel et al., 2006). In brief, lung tissuewas
minced into 1 mm3 sections and cultured with 10% heat in-
activated FBS on scored tissue culture dishes. After 10–14days, the fibroblasts derived from the explants were trypsinized
and maintained in culture. Cells at low passage (3–5) were used
in these experiments. Some of the experiments were done on
cells that had been frozen down. All the cells were vimentin
positive.
SARS-CoV infection of type II and type I-like cells and primary
fibroblasts
Medium was aspirated from both sides of the Millicell inserts
(type II cells) or from the wells (type I cells). Monolayers were
washed briefly with 2 mL MEM supplemented with 2% FBS
(MEM/2%). A second wash was added and left to stand 15 min
at room temperature (RT). The second wash was aspirated and
to the interior chamber of each insert (type II) or well (type I)
was added 250 μL SARS-CoV stock (MOI=2–3) or 250 μL
MEM/2% for mock-infections. Cells were placed at 37 °C in
5% CO2 atmosphere for 1 h. After adsorption, inoculum was
aspirated and cell monolayers were washed four times with
MEM/2%. After the final wash of type II cell cultures, 0.5 mL
media was added to the interior of the Millicell insert and
1.5 mL media was added to the exterior. After the final wash of
type I-like cells, 2 mL type I cell medium was added to each
well. Cultures were incubated at 37 °C in 10% CO2 atmosphere.
At indicated time points 100 μL aliquots of medium were
removed and stored at −80 °C until analysis and replaced with
equal volumes of cell type appropriate fresh medium.
Western blotting
Protein expression was measured by Western blotting ac-
cording to protocols described previously (Wang et al., 2007).
Polyacrylamide gradient gels (8–16%) from Invitrogen Corp.,
Carlsbad, CA, USA, were run in Tris glycine buffer to separate
proteins. Proteins were run in their reduced state except for SP-B,
which was run unreduced. For Western blotting, protein loading
was normalized to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH).
Multiplex RT-PCR
After removal of the culture medium, 250 μL TRIzol LS
reagent (Invitrogen) was added to the cell monolayers for 2–
4min at room temperature. RNAwas extracted from the solution
per the manufacturer's protocol. Multiplex RT-PCR for the si-
multaneous detection of SARS-CoV genomic and subgenomic
RNA as well as cellular GAPDHwas performed as described by
Gillim-Ross et al. (2004).
Immunocytochemistry
Type II cells were fixed and stained on intact inserts. Type I-
like cells were fixed and stained on rat tail collagen-coated
coverslips within 6-well tissue culture plates. Cells were fixed
10–15 min in 100% methanol at −20 °C or overnight in 4%
paraformaldehyde at 4 °C. Coverslips and inserts were stored in
PBS at 4 °C up to 2 weeks prior to staining. Immunostaining
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Paraformaldehyde fixed filters were permeabilized with 0.2%
triton X-100. Methanol-fixed cells were not treated with triton.
After blocking with normal serum, the cells were incubated with
primary antibodies for 1 h. The primary antibodies were: SARS
nucleocapsid (IMG-548, Imgenex, San Diego, CA, USA), SP-A
(PE-10, a gift from Dr. Yoshio Kuroki, Sapporo, Japan), cyto-
keratin (CAM5.2, Becton Dickinson, San Jose, CA, USA), Ep-
CAM (Chemicon International, Temecula, CA, USA), an anti-
body specific for human type II cells (generously provided by
Leland Dobbs, UCSF (Fang et al., 2006), vimentin (V9, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), CD-31 (JC70A,
Dako, Carpinteria, CA, USA), CD-45 (BD Biosciences, San
Jose, CA, USA) and collagen III (SC-28888, Santa Cruz Bio-
technology). The secondary antibodies, Alexa 488 anti-rabbit
IgG and/or Alexa 594 anti-mouse IgG (Invitrogen) were incu-
bated with the cells for 1 h. Cells were mounted with Vecta-
shield containing DAPI (Vector Laboratories, Burlingame, CA,
USA) to visualize nuclei.
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